Key result
Direct plasmin inhibition with YO-2 aggravates atherosclerosis in mice, unlike tranexamic acid.
Why the study?
The effects of distinct antifibrinolytic interventions on atherosclerosis progression and extracellular matrix remodeling remain unclear.
Does direct plasmin inhibition with YO-2 or tranexamic acid affect atherosclerosis progression and vascular remodeling in Apoe/Ldlr double-knockout mice on a Western diet?
Does direct plasmin inhibition with YO-2 or tranexamic acid affect atherosclerosis progression and vascular remodeling in Apoe/Ldlr double-knockout mice on a Western diet?
p-value: p=<0.05
In a preclinical atherosclerosis model, direct plasmin inhibition with YO-2 aggravated atherosclerosis and altered vascular remodeling, whereas the lysine analog TXA had minimal effect on lesion burden, highlighting distinct mechanistic roles of different antifibrinolytic pathways.
Direct plasmin inhibition may promote atherosclerosis in this model; leaves open differential antifibrinolytic effects on human plaque progression.
AIM: The fibrinolytic system may protect against or promote atherosclerosis; however, the effects of distinct antifibrinolytic interventions on plaque development and extracellular matrix (ECM) remodeling remain unclear. METHODS: We compared YO-2, a direct plasmin inhibitor, and tranexamic acid (TXA), a lysine analog that interferes with plasminogen/plasmin binding to fibrin, in Apoe/Ldlr double-knockout mice fed a Western diet. The atherosclerotic burden, plaque structure, vascular marker expression, leukocyte-endothelial interactions, and nitric oxide (NO)-related indices were assessed. RESULTS: YO-2 significantly increased the atherosclerotic lesion area compared to the control, whereas TXA had minimal effects. The thrombolytic activity in the He-Ne laser-induced thrombosis model and NO-related indices did not differ significantly among the groups. Vascular t-PA expression increased in both treatment groups. YO-2 was associated with reduced uPAR and MMP-9 expression and preservation of the internal elastic lamina and medial elastin fibers, suggesting reduced pericellular ECM degradation. TXA increased PAI-1 and TAFI expression without altering uPAR. Both treatments significantly reduced leukocyte rolling, and the E-selectin expression was significantly decreased with YO-2, with a similar trend with TXA. eNOS mRNA expression was significantly higher in both groups, although the corresponding increase in the eNOS protein expression was only a non-significant trend. CONCLUSIONS: Direct plasmin inhibition with YO-2 aggravated atherosclerosis and it was associated with a reduced uPAR/MMP-9 expression and altered vascular ECM remodeling. TXA had limited effects on lesion burden while increasing PAI-1 and TAFI expression. These findings suggest that direct plasmin inhibition and TXA-mediated antifibrinolysis may differentially affect atherosclerosis and vascular remodeling.
No takes yet. Share an insight, caveat, or question.
Yoshihama et al. (2026) studied Atherosclerosis (n=107). YO-2 and Tranexamic Acid vs. Control (Western diet) was evaluated on Atherosclerotic lesion area (p=<0.05). Direct plasmin inhibition with YO-2 significantly aggravated atherosclerosis and altered vascular extracellular matrix remodeling in mice, whereas tranexamic acid had limited effects on lesion burden.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: